Spirogen Ltd.

The QMB Innovation Centre, 42 New Road,
London, E1 2AX
United Kingdom,
+44 20 7278 0555
www.spirogen.com

The Spirogen group was founded in 2001 as a spin-out from several institutions including University College London and with partial funding by Cancer Research UK. It is majority owned by Auven Therapeutics. It has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (PBDs), DNA minor groove binding agents, which bind and cross-link specific sites of DNA of the cancer cell.

Spirogen was acquired by MedImmune on October 15, 2013.

Join Mergr to view all 177 acquisitions of life science companies in 2013, including 20 acquisitions by private equity firms, and 157 by strategics.

Out of 60 sectors in the Mergr database, life science ranked 10 in number of deals in 2013. The largest life science acquisition in 2013 was Onyx Pharmaceuticals - which was acquired by Amgen for $10.4B.

Join Mergr to view this profile - and discover more life science acquisitions of companies like Spirogen.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.2K Private Equity Firms
  • 111K M&A Transactions
  • 120K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 38K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.